Sample Test Reports

Tap or click on the images below to view, download, or print sample test reports.

Glioblastoma (GBM)

Sample Summit 2.0, Ascent, and Vantage cerebrospinal fluid liquid biopsy report showing a positive result for glioblastoma, with TERT mutation, EGFR, CDK4, and MDM2 amplifications, chromosome 7 gain and chromosome 10 loss, and MGMT methylation detected. — Belay Summit 2.0, Ascent & Vantage Report – Positive GBM

Oligodendroglioma

Sample Ascent report showing a positive result for oligodendroglioma, with 1p/19q codeletion detected and alkylating agent therapy implications per NCCN. — Belay Ascent Report – Positive Oligodendroglioma

Primary CNS Lymphoma (PCNSL)

Sample Summit 2.0 plus Vantage combined report showing a positive result for primary CNS lymphoma, with MYD88, CD79B, CDKN1B, and PIM1 variants detected and MGMT methylation noted. — Belay Summit 2.0 & Vantage Report – Positive PCNSL

Brain Metastases – Breast

Sample Summit 2.0 report showing a positive result for metastatic breast carcinoma with CNS involvement, with ERBB2 amplification and TP53 and ARID1A variants detected. — Belay Summit 2.0 Report – Positive Brain Metastases

Sample Summit 2.0 report showing a negative result for metastatic breast carcinoma with CNS involvement, with variants of unknown significance noted. — Belay Summit 2.0 Report – Negative Brain Metastases

Sample Ascent report showing a negative result for metastatic breast carcinoma with CNS involvement, with no chromosomal arm-level alterations detected. — Belay Ascent Report – Negative Brain Metastases

Brain Metastases – Lung

Sample Summit 2.0 and Ascent cerebrospinal fluid liquid biopsy report for metastatic non-small cell lung carcinoma with CNS involvement, featuring serial CSF testing with VAF trend and aneuploidy charts showing tumor evolution over time, with EML4-ALK fusion detected. — Belay Summit 2.0 & Ascent Report – Positive Lung Metastases, Serial

Central Nervous System Neoplasm (Unspecified/General)

Sample Belay Diagnostics Vantage cerebrospinal fluid liquid biopsy report showing MGMT promoter methylation detected, with therapeutic and prognostic implications per NCCN. — Belay Vantage Report – MGMT Positive CNS

Sample Vantage MGMT promoter methylation report showing a negative result for a central nervous system neoplasm patient, with temozolomide resistance implications per NCCN. — Belay Vantage Report – MGMT Negative CNS

Sample Summit 2.0 and Ascent combined report showing a negative result for a central nervous system neoplasm, with no clinically significant alterations and no chromosomal arm-level changes detected. — Belay Summit 2.0 & Ascent Report – Negative CNS

Sample Summit 2.0, Ascent, and Vantage combined report showing a negative result for a central nervous system neoplasm, with no clinically significant alterations, no aneuploidy, and MGMT unmethylated. — Belay Summit 2.0, Ascent & Vantage Report – Negative CNS